PMID- 25458857
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20240324
IS  - 1573-2509 (Electronic)
IS  - 0920-9964 (Print)
IS  - 0920-9964 (Linking)
VI  - 176
IP  - 1
DP  - 2016 Sep
TI  - Anti-NMDA receptor encephalitis, autoimmunity, and psychosis.
PG  - 36-40
LID - S0920-9964(14)00546-5 [pii]
LID - 10.1016/j.schres.2014.10.007 [doi]
AB  - Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis is a recently-discovered 
      synaptic autoimmune disorder in which auto-antibodies target NMDARs in the brain, 
      leading to their removal from the synapse. Patients manifest with prominent 
      psychiatric symptoms - and in particular psychosis - early in the disease course. 
      This presentation converges with long-standing evidence on multiple fronts 
      supporting the glutamatergic model of schizophrenia. We review mechanisms 
      underlying disease in anti-NMDAR encephalitis, and discuss its role in furthering 
      our understanding of neural circuit dysfunction in schizophrenia.
CI  - Copyright (c) 2014 Elsevier B.V. All rights reserved.
FAU - Kayser, Matthew S
AU  - Kayser MS
AD  - Department of Psychiatry, Perelman School of Medicine, University of 
      Pennsylvania, United States; Center for Sleep and Circadian Biology, Perelman 
      School of Medicine, University of Pennsylvania, United States. Electronic 
      address: Matthew.Kayser@uphs.upenn.edu.
FAU - Dalmau, Josep
AU  - Dalmau J
AD  - Department of Neurology, Perelman School of Medicine, University of Pennsylvania, 
      United States; Department of Neurology, Hospital Clinic, Barcelona, Spain.
LA  - eng
GR  - R01 MH094741/MH/NIMH NIH HHS/United States
GR  - R01 NS077851/NS/NINDS NIH HHS/United States
GR  - T32 HL007713/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20141025
PL  - Netherlands
TA  - Schizophr Res
JT  - Schizophrenia research
JID - 8804207
SB  - IM
MH  - Anti-N-Methyl-D-Aspartate Receptor Encephalitis/*immunology
MH  - Autoimmunity/*immunology
MH  - Humans
MH  - Psychotic Disorders/*immunology
MH  - Schizophrenia/*immunology
PMC - PMC4409922
MID - NIHMS635979
OTO - NOTNLM
OT  - Autoimmune
OT  - Encephalitis
OT  - NMDA
OT  - Schizophrenia
COIS- Conflicts JD receives royalties from Athena Diagnostics for a patent for the use 
      of Ma2 as an autoantibody test, and licensing fees from Euroimmun for a patent 
      for the use of NMDAR as an autoantibody test. MK reports no competing interests.
EDAT- 2014/12/03 06:00
MHDA- 2017/12/28 06:00
PMCR- 2017/09/01
CRDT- 2014/12/03 06:00
PHST- 2014/07/16 00:00 [received]
PHST- 2014/10/06 00:00 [revised]
PHST- 2014/10/08 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
AID - S0920-9964(14)00546-5 [pii]
AID - 10.1016/j.schres.2014.10.007 [doi]
PST - ppublish
SO  - Schizophr Res. 2016 Sep;176(1):36-40. doi: 10.1016/j.schres.2014.10.007. Epub 
      2014 Oct 25.